CALR突变骨髓增殖性肿瘤中CALR等位基因负荷动态与疾病进展相关
该研究对45例CALR突变原发性血小板增多症患者进行诊断时及随访中的二代测序与CALR等位基因负荷检测,并盲法复习骨髓病理以应用WHO2016分类。
要点
- CALR突变ET患者随访中CALR等位基因负荷增加与疾病进展相关。
- 该关联独立于附加突变及WHO2016复核诊断。
核心结论
- CALR突变ET患者随访期间CALR等位基因负荷增加与疾病进展相关,独立于附加突变和WHO2016复核诊断。
- 结果提示CALR等位基因负荷监测具有临床意义。
研究设计与样本
- 对45例CALR突变原发性血小板增多症患者,在诊断时及随访中进行二代测序(髓系panel)与CALR等位基因负荷检测。
- 骨髓组织学盲法复核以应用WHO2016分类。
主要发现
- 最常突变基因为TET2(21个突变中11个)。
- CALR 1型样患者分子景观似乎更复杂。
临床怎么用
- 对CALR突变ET患者可考虑系列监测CALR等位基因负荷以辅助评估疾病进展。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
In myeloproliferative neoplasms (MPN), JAK2V617F allele burden measurement has an impact on prognosis that helps in patient monitoring. Less is known about its usefulness in CALR-mutated cases. Additional mutations found by next-generation sequencing have also shown an impact on prognosis that may drive therapeutic choices, especially in myelofibrosis, but few studies focused on CALR-mutated patients. We performed a molecular evaluation combining next-generation sequencing with a myeloid panel and CALR allele burden measurement at diagnosis and during follow-up in a cohort of 45 patients with CALR-mutated essential thrombocythaemia. The bone marrow histology was also blindly reviewed in order to apply the WHO2016 classification. The most frequently mutated gene was TET2 (11/21 mutations). CALR type 1-like patients appear to have a more complex molecular landscape. We found an association between disease progression and CALR allele burden increase during follow-up, independently of additional mutations and WHO2016-reviewed diagnosis. Patients with disease progression at the time of follow-up showed a significant increase in CALR allele burden (+16·7%, P = 0·005) whereas patients without disease progression had a stable allele burden (+3·7%, P = 0·194). This result argues for clinical interest in CALR allele burden monitoring.
引用
- Cottin L, Riou J, Orvain C, et al. Sequential mutational evaluation of CALR -mutated myeloproliferative neoplasms with thrombocytosis reveals an association between CALR allele burden evolution and disease progression. Br J Haematol. 2019. PMID: 31710700. doi:10.1111/bjh.16276
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。